Keywords:
Autoantibodies; continuous glucose monitoring; dysglycaemia; intervention trials; pre-symptomatic diabetes; type 1 diabetes
Abstract:
Type 1 diabetes is well-recognised as a continuum heralded by the development of islet autoantibodies, progression to islet autoimmunity causing beta cell destruction, culminating in insulin deficiency and clinical disease. Abnormalities of glucose homeostasis are known to exist well before the onset of typical symptoms.